drugset / Trial / NCT06446310
Phase 3 Study of QLG2198 in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This a multicentre study that consists of a 12-week double-blind period, and a 14-week open-label extension period and a 1-week follow-up period.
Timeline
- Start
- 2024-06-18
- Primary completion
- 2025-02-21
- Completion
- 2025-08-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QLG2198 | Unknown | 0.5 ug/kg | Intravenous |
Indications
No indication recorded.